Dextromethadone - Relmada Therapeutics

Drug Profile

Dextromethadone - Relmada Therapeutics

Alternative Names: +-Methadone - Relmada Therapeutics; 6S-Methadone - Relmada Therapeutics; d Methadone - Relmada Therapeutics; REL 1017; S-Methadone - Relmada Therapeutics

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Relmada Therapeutics
  • Class Analgesics; Drug withdrawal therapies; Ketones
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Major depressive disorder

Most Recent Events

  • 13 Apr 2017 Dextromethadone - Relmada Therapeutics receives Fast Track designation for Major depressive disorder (Adjunctive treatment) [PO] in USA
  • 25 Jan 2017 U.S. Food and Drug Administration (FDA) approves IND application for dextromethadone in Depression (Treatment-resistant)
  • 19 Oct 2016 Relmada Therapeutics has patent protection for dextromethadone in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top